UCB sells generics unit to Lannett

Home/Pharma News | Posted 11/09/2015 post-comment0 Post your comment

Belgium-based biopharmaceutical company UCB announced on 2 September 2015 that it would sell its US specialty generics business, Kremers Urban, to US generics company Lannett for US$1.23 billion in cash plus contingent payments.

Generics Blue Cap V13C15

The news follows UCB’s failed attempt to sell the US generics business to private equity firms Advent International and Avista Capital Partners for US$1.53 billion in December 2014. That deal collapsed after the US Food and Drug Administration (FDA) asked for further studies on its generic version of Johnson & Johnson’s Concerta (methylphenidate) pill for attention deficit hyperactivity (ADHD).

The acquisition will boost Lannetts’ generics portfolio, bringing 18 commercialized products into the Lannett offering, and including generics for ADHD, high blood pressure, respiratory diseases and gastroesophageal reflux. While on the other hand, it will allow UCB to concentrate on its innovative medicines pipeline. This new focus by UCB was also in evidence in its decision to sell its Indian established brands portfolio to Dr Reddy’s in April 2015.

Lannett will also gain a strong pipeline that includes 11 product applications pending at FDA, of which five include Paragraph IV certifications, and 17 product candidates in various stages of development, including one 505(b)(2) product opportunity. Kremers Urban brings additional research and development and regulatory expertise, particularly in the areas of difficult-to-manufacture products and Paragraph IV certifications. As part of the transaction, Lannett will also receive Kremers Urban’s recently inspected 381,000 square foot state-of-the-art facility in Seymour, Indiana, USA, which has substantial manufacturing and warehousing capacity, as well as dedicated product development space.

The deal is expected to be finalized in the fourth quarter of 2015 and has been unanimously approved by the Boards of Directors of both Lannett and UCB.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.

Source: Lannett, UCB

comment icon Comments (0)
Post your comment
Related content
Novartis is set to spin-off Sandoz
Guidance V13F21
Home/Pharma News Posted 16/09/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010